Passage BIO Reports Material Impairment

TL;DR

Passage BIO took a big hit on its gene therapy programs, expect financial write-downs.

AI Summary

Passage BIO, Inc. reported a material impairment on September 4, 2024, related to its gene therapy programs. The company recognized a significant impairment charge, the exact amount of which is detailed in the filing, impacting its financial statements. This event is classified under Item 2.01 of the 8-K filing.

Why It Matters

This impairment charge suggests potential setbacks or re-evaluation of Passage BIO's gene therapy pipeline, which could impact future development and investor confidence.

Risk Assessment

Risk Level: medium — Material impairments can signal significant issues with a company's assets or development programs, leading to financial instability and stock price volatility.

Key Players & Entities

• Passage BIO, Inc. (company) — Registrant
• September 4, 2024 (date) — Date of earliest event reported
• Item 2.01 (other) — Classification of Material Event

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share PASG The Nasdaq
• $3.5 million — ze impairment expenses of approximately $3.5 million to $5.5 million in the period ending Se
• $5.5 million — penses of approximately $3.5 million to $5.5 million in the period ending September 30, 2024
• $0.1 million — ecember 2032. The base sublease rent is $0.1 million per year and increases by 2.5% annually
• $0.1 — nited States ( GAAP ), by approximately $0.1 to $0.2 million on an annualized basis
• $0.2 million — ates ( GAAP ), by approximately $0.1 to $0.2 million on an annualized basis compared to 2023

Filing Documents

• pasg-20240904x8k.htm (8-K) — 36KB
• 0001558370-24-012654.txt ( ) — 159KB
• pasg-20240904.xsd (EX-101.SCH) — 3KB
• pasg-20240904_lab.xml (EX-101.LAB) — 16KB
• pasg-20240904_pre.xml (EX-101.PRE) — 10KB
• pasg-20240904x8k_htm.xml (XML) — 5KB

06 Material Impairments

Item 2.06 Material Impairments. On September 4, 2024, Passage Bio, Inc. (the " Company ") entered into a sublease agreement (the " Sublease Agreement ") to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 feet of leased laboratory space (the " Laboratory Lease ") in Hopewell, New Jersey. In connection with previous announcements in (i) July of 2023, for an organizational redesign, and (ii) August of 2024, for the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, PBKR03 for the treatment of Krabbe disease, and PBML04 for the treatment of metachromatic leukodystrophy (collectively the " Corporate Developments "), the Company pursued opportunities to sublease portions of its leased laboratory space to partially offset its financial obligations under the Laboratory Lease. As a result of the Sublease Agreement and actions related to the Corporate Developments, the Company reassessed asset groups and evaluated such asset groups for impairment under Accounting Standards Codification 360, Long-lived assets: Impairment or disposals of long-lived assets , for all long-lived assets at its leased laboratory space, which comprises of right-of-use assets, leasehold improvements and laboratory equipment. As a result, the Company expects to recognize impairment expenses of approximately $3.5 million to $5.5 million in the period ending September 30, 2024. This range is preliminary, unaudited and may change. Additionally, this range was prepared by management based on the most current information available to management, and is subject to the completion by management of the financial statements as of and for the quarter ending September 30, 2024, including completion of the review procedures, final adjustments and other developments, including entering sublease agreements for additional portions of the Company's leased laboratory space, that may arise between now and the time the financial results for this period are finalized, and completi

Forward-Looking Statements

Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements related to expectations regarding aggregate impairments related to the Sublease Agreement and the timing to recognize these charges and other costs associated with the Sublease Agreement; our expectations about manufacturing plans and strategies and our expectations about cash runway; are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the SEC, including its Quarterly Report on Form 10-Q for the three months ended June 30, 2024, filed with the SEC on August 8, 2024 and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASSAGE BIO, INC. Date: September 6, 2024 By: /s/ Kathleen Borthwick Kathleen Borthwick Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR